Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

benzinga.com/news/health-care/25/06/45801433/valnevas-chikungunya-vaccine-advances-with-pediatric-trial-phase-3-in-2026

Valneva SE (NASDAQ:VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, Ixchiq, in 304 children, according to a press release.…

This story appeared on benzinga.com, 2025-06-05 19:09:47.
The Entire Business World on a Single Page. Free to Use →